pioglitazone has been researched along with 2-fluoro-2-deoxyglucose-6-phosphate in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Halter, RJ; Ihle, NT; Kirkpatrick, L; Lemos, R; Oh, J; Powis, G; Schwartz, D; Wipf, P | 1 |
1 other study(ies) available for pioglitazone and 2-fluoro-2-deoxyglucose-6-phosphate
Article | Year |
---|---|
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Progression; Glucose; Glucose Transport Proteins, Facilitative; Glucose-6-Phosphate; Gonanes; Humans; Hyperglycemia; Mice; Neoplasms; Phosphatidylinositol 3-Kinases; Pioglitazone; PPAR gamma; Signal Transduction; Thiazolidinediones; Xenograft Model Antitumor Assays | 2009 |